{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:39:39Z","timestamp":1791297579716,"version":"4.1.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"5","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Melanoma has a propensity to metastasize to bone, where it is exposed to high concentrations of transforming growth factor-\u03b2 (TGF-\u03b2). Because TGF-\u03b2 promotes bone metastases from other solid tumors, such as breast cancer, we tested the role of TGF-\u03b2 in melanoma metastases to bone. 1205Lu melanoma cells, stably transfected to overexpress the natural TGF-\u03b2\/Smad signaling inhibitor Smad7, were studied in an experimental model of bone metastasis whereby tumor cells are inoculated into the left cardiac ventricle of nude mice. All mice bearing parental and mock-transfected 1205Lu cells developed osteolytic bone metastases 5 weeks post-tumor inoculation. Mice bearing 1205Lu-Smad7 tumors had significantly less osteolysis on radiographs and longer survival compared with parental and mock-transfected 1205Lu mice. To determine if the reduced bone metastases observed in mice bearing 1205Lu-Smad7 clones was due to reduced expression of TGF-\u03b2 target genes known to enhance metastases to bone from breast cancer cells, we analyzed gene expression of osteolytic factors, parathyroid hormone-related protein (PTHrP) and interleukin-11 (IL-11), the chemotactic receptor CXCR4, and osteopontin in 1205Lu cells. Quantitative reverse transcription-PCR analysis indicated that PTHrP, IL-11, CXCR4, and osteopontin mRNA steady-state levels were robustly increased in response to TGF-\u03b2 and that Smad7 and the T\u03b2RI small-molecule inhibitor, SB431542, prevented such induction. In addition, 1205Lu-Smad7 bone metastases expressed significantly lower levels of IL-11, connective tissue growth factor, and PTHrP. These data suggest that TGF-\u03b2 promotes osteolytic bone metastases due to melanoma by stimulating the expression of prometastatic factors via the Smad pathway. Blockade of TGF-\u03b2 signaling may be an effective treatment for melanoma metastasis to bone. [Cancer Res 2007;67(5):2317\u201324]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-3950","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T03:03:59Z","timestamp":1172804639000},"page":"2317-2324","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":174,"title":["Stable Overexpression of Smad7 in Human Melanoma Cells Impairs Bone Metastasis"],"prefix":"10.1158","volume":"67","author":[{"given":"Delphine","family":"Javelaud","sequence":"first","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale, U697, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid S.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"2University of Virginia, Charlottesville, Virginia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"McKenna","sequence":"additional","affiliation":[{"name":"2University of Virginia, Charlottesville, Virginia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick","family":"Fournier","sequence":"additional","affiliation":[{"name":"2University of Virginia, Charlottesville, Virginia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavie","family":"Luciani","sequence":"additional","affiliation":[{"name":"3UMR146 Centre National de Recherche Scientifique, Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryla","family":"Niewolna","sequence":"additional","affiliation":[{"name":"2University of Virginia, Charlottesville, Virginia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyne","family":"Andre\u0301","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale, U697, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ve\u0301ronique","family":"Delmas","sequence":"additional","affiliation":[{"name":"3UMR146 Centre National de Recherche Scientifique, Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Larue","sequence":"additional","affiliation":[{"name":"3UMR146 Centre National de Recherche Scientifique, Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Guise","sequence":"additional","affiliation":[{"name":"2University of Virginia, Charlottesville, Virginia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mauviel","sequence":"additional","affiliation":[{"name":"1Institut National de la Sante et de la Recherche Medicale, U697, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,3,1]]},"reference":[{"key":"2022061623345656300_B1","doi-asserted-by":"crossref","unstructured":"Roberts AB, Russo A, Felici A, Flanders KC. Smad3: a key player in pathogenetic mechanisms dependent on TGF-\u03b2. Ann N Y Acad Sci\u20082003; 995: 1\u201310.","DOI":"10.1111\/j.1749-6632.2003.tb03205.x"},{"key":"2022061623345656300_B2","doi-asserted-by":"crossref","unstructured":"Cohen MM Jr. TGF \u03b2\/Smad signaling system and its pathologic correlates. Am J Med Genet\u20082003; 116A: 1\u201310.","DOI":"10.1002\/ajmg.a.10750"},{"key":"2022061623345656300_B3","doi-asserted-by":"crossref","unstructured":"Verrecchia F, Mauviel A. Transforming growth factor-\u03b2 signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol\u20082002; 118: 211\u20135.","DOI":"10.1046\/j.1523-1747.2002.01641.x"},{"key":"2022061623345656300_B4","doi-asserted-by":"crossref","unstructured":"Chen W, Wahl SM. TGF-\u03b2: receptors, signaling pathways, and autoimmunity. Curr Dir Autoimmun\u20082002; 5: 62\u201391.","DOI":"10.1159\/000060548"},{"key":"2022061623345656300_B5","doi-asserted-by":"crossref","unstructured":"Javelaud D, Mauviel A. Mammalian transforming growth factor-\u03b2s: Smad signaling and physio-pathological roles. Int J Biochem Cell Biol\u20082004; 36: 1161\u20135.","DOI":"10.1016\/S1357-2725(03)00255-3"},{"key":"2022061623345656300_B6","doi-asserted-by":"crossref","unstructured":"Akhurst RJ. TGF-\u03b2 antagonists: why suppress a tumor suppressor? J Clin Invest\u20082002; 109: 1533\u20136.","DOI":"10.1172\/JCI0215970"},{"key":"2022061623345656300_B7","doi-asserted-by":"crossref","unstructured":"Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-\u03b2 in homeostasis and cancer. Nat Rev Cancer\u20082003; 3: 807\u201321.","DOI":"10.1038\/nrc1208"},{"key":"2022061623345656300_B8","doi-asserted-by":"crossref","unstructured":"Wakefield LM, Roberts AB. TGF-\u03b2 signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev\u20082002; 12: 22\u20139.","DOI":"10.1016\/S0959-437X(01)00259-3"},{"key":"2022061623345656300_B9","doi-asserted-by":"crossref","unstructured":"Shi Y, Massague J. Mechanisms of TGF-\u03b2 signaling from cell membrane to the nucleus. Cell\u20082003; 113: 685\u2013700.","DOI":"10.1016\/S0092-8674(03)00432-X"},{"key":"2022061623345656300_B10","doi-asserted-by":"crossref","unstructured":"Nakao A, Okumura K, Ogawa H. Smad7: a new key player in TGF-\u03b2-associated disease. Trends Mol Med\u20082002; 8: 361\u20133.","DOI":"10.1016\/S1471-4914(02)02376-6"},{"key":"2022061623345656300_B11","doi-asserted-by":"crossref","unstructured":"Shi W, Sun C, He B, et al. GADD34-PP1c recruited by Smad7 dephosphorylates TGF\u03b2 type I receptor. J Cell Biol\u20082004; 164: 291\u2013300.","DOI":"10.1083\/jcb.200307151"},{"key":"2022061623345656300_B12","doi-asserted-by":"crossref","unstructured":"Komuro A, Imamura T, Saitoh M, et al. Negative regulation of transforming growth factor-\u03b2 (TGF-\u03b2) signaling by WW domain-containing protein 1 (WWP1). Oncogene\u20082004; 23: 6914\u201323.","DOI":"10.1038\/sj.onc.1207885"},{"key":"2022061623345656300_B13","doi-asserted-by":"crossref","unstructured":"Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE. Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res\u20081995; 139: 169\u201382.","DOI":"10.1007\/978-3-642-78771-3_12"},{"key":"2022061623345656300_B14","unstructured":"Rodeck U, Nishiyama T, Mauviel A. Independent regulation of growth and SMAD-mediated transcription by transforming growth factor \u03b2 in human melanoma cells. Cancer Res\u20081999; 59: 547\u201350."},{"key":"2022061623345656300_B15","doi-asserted-by":"crossref","unstructured":"Javelaud D, Delmas V, Moller M, et al. Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene\u20082005; 24: 7624\u20139.","DOI":"10.1038\/sj.onc.1208900"},{"key":"2022061623345656300_B16","doi-asserted-by":"crossref","unstructured":"Yin JJ, Selander K, Chirgwin JM, et al. TGF-\u03b2 signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest\u20081999; 103: 197\u2013206.","DOI":"10.1172\/JCI3523"},{"key":"2022061623345656300_B17","doi-asserted-by":"crossref","unstructured":"Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell\u20082003; 3: 537\u201349.","DOI":"10.1016\/S1535-6108(03)00132-6"},{"key":"2022061623345656300_B18","doi-asserted-by":"crossref","unstructured":"Mundy GR. Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer\u20082002; 2: 584\u201393.","DOI":"10.1038\/nrc867"},{"key":"2022061623345656300_B19","doi-asserted-by":"crossref","unstructured":"Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia\u20082005; 10: 169\u201380.","DOI":"10.1007\/s10911-005-5399-8"},{"key":"2022061623345656300_B20","doi-asserted-by":"crossref","unstructured":"Rodeck U, Melber K, Kath R, et al. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol\u20081991; 97: 20\u20136.","DOI":"10.1111\/1523-1747.ep12477822"},{"key":"2022061623345656300_B21","unstructured":"MacDougall JR, Kobayashi H, Kerbel RS. Responsiveness of normal, dysplastic melanocytes and melanoma cells from different lesional stages of disease progression to the growth inhibitory effects of TGF-\u03b2. Mol Cell Diff\u20081993; 1: 21\u201340."},{"key":"2022061623345656300_B22","doi-asserted-by":"crossref","unstructured":"Moore R, Champeval D, Denat L, et al. Involvement of cadherins 7 and 20 in mouse embryogenesis and melanocyte transformation. Oncogene\u20082004; 23: 6726\u201335.","DOI":"10.1038\/sj.onc.1207675"},{"key":"2022061623345656300_B23","doi-asserted-by":"crossref","unstructured":"Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF \u03b2-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J\u20081998; 17: 3091\u2013100.","DOI":"10.1093\/emboj\/17.11.3091"},{"key":"2022061623345656300_B24","doi-asserted-by":"crossref","unstructured":"Javelaud D, Laboureau J, Gabison E, Verrecchia F, Mauviel A. Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing. J Biol Chem\u20082003; 278: 24624\u20138.","DOI":"10.1074\/jbc.M301942200"},{"key":"2022061623345656300_B25","doi-asserted-by":"crossref","unstructured":"Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-\u03b2 and prevents bleomycin-mediated lung fibrosis. J Clin Invest\u20082004; 114: 1308\u201316.","DOI":"10.1172\/JCI200419603"},{"key":"2022061623345656300_B26","doi-asserted-by":"crossref","unstructured":"Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest\u20081996; 98: 1544\u20139.","DOI":"10.1172\/JCI118947"},{"key":"2022061623345656300_B27","doi-asserted-by":"crossref","unstructured":"Vindevoghel L, Lechleider RJ, Kon A, et al. SMAD3\/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor \u03b2. Proc Natl Acad Sci U S A\u20081998; 95: 14769\u201374.","DOI":"10.1073\/pnas.95.25.14769"},{"key":"2022061623345656300_B28","unstructured":"Berking C, Takemoto R, Schaider H, et al. Transforming growth factor-\u03b21 increases survival of human melanoma through stroma remodeling. Cancer Res\u20082001; 61: 8306\u201316."},{"key":"2022061623345656300_B29","doi-asserted-by":"crossref","unstructured":"Xu W, Angelis K, Danielpour D, et al. Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type \u03b2 transforming growth factor. Proc Natl Acad Sci U S A\u20082000; 97: 5924\u20139.","DOI":"10.1073\/pnas.090097797"},{"key":"2022061623345656300_B30","unstructured":"Reed JA, Bales E, Xu W, Okan NA, Bandyopadhyay D, Medrano EE. Cytoplasmic localization of the oncogenic protein ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor \u03b2 signaling. Cancer Res\u20082001; 61: 8074\u20138."},{"key":"2022061623345656300_B31","doi-asserted-by":"crossref","unstructured":"Medrano EE. Repression of TGF-\u03b2 signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene\u20082003; 22: 3123\u20139.","DOI":"10.1038\/sj.onc.1206452"},{"key":"2022061623345656300_B32","unstructured":"Gold LI. The role for transforming growth factor-\u03b2 (TGF-\u03b2) in human cancer. Crit Rev Oncog\u20081999; 10: 303\u201360."},{"key":"2022061623345656300_B33","doi-asserted-by":"crossref","unstructured":"Derynck R, Akhurst RJ, Balmain A. TGF-\u03b2 signaling in tumor suppression and cancer progression. Nat Genet\u20082001; 29: 117\u201329.","DOI":"10.1038\/ng1001-117"},{"key":"2022061623345656300_B34","doi-asserted-by":"crossref","unstructured":"Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE. Elevated plasma levels of transforming growth factor (TGF)-\u03b21 and TGF-\u03b22 in patients with disseminated malignant melanoma. Br J Cancer\u20081998; 77: 1492\u20134.","DOI":"10.1038\/bjc.1998.245"},{"key":"2022061623345656300_B35","doi-asserted-by":"crossref","unstructured":"Krasagakis K, Kruger-Krasagakes S, Fimmel S, et al. Desensitization of melanoma cells to autocrine TGF-\u03b2 isoforms. J Cell Physiol\u20081999; 178: 179\u201387.","DOI":"10.1002\/(SICI)1097-4652(199902)178:2<179::AID-JCP7>3.0.CO;2-5"},{"key":"2022061623345656300_B36","unstructured":"Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res\u20081988; 48: 6876\u201381."},{"key":"2022061623345656300_B37","doi-asserted-by":"crossref","unstructured":"Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast \u03b23 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A\u20082003; 100: 14205\u201310.","DOI":"10.1073\/pnas.2234372100"},{"key":"2022061623345656300_B38","doi-asserted-by":"crossref","unstructured":"Ohno H, Kubo K, Murooka H, et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther\u20082006; 5: 2634\u201343.","DOI":"10.1158\/1535-7163.MCT-05-0313"},{"key":"2022061623345656300_B39","doi-asserted-by":"crossref","unstructured":"Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest\u20082005; 115: 44\u201355.","DOI":"10.1172\/JCI22320"},{"key":"2022061623345656300_B40","doi-asserted-by":"crossref","unstructured":"Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A\u20082005; 102: 13909\u201314.","DOI":"10.1073\/pnas.0506517102"},{"key":"2022061623345656300_B41","doi-asserted-by":"crossref","unstructured":"Deckers M, van Dinther M, Buijs J, et al. The tumor suppressor Smad4 is required for transforming growth factor \u03b2-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res\u20082006; 66: 2202\u20139.","DOI":"10.1158\/0008-5472.CAN-05-3560"},{"key":"2022061623345656300_B42","doi-asserted-by":"crossref","unstructured":"Azuma H, Ehata S, Miyazaki H, et al. Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst\u20082005; 97: 1734\u201346.","DOI":"10.1093\/jnci\/dji399"},{"key":"2022061623345656300_B43","doi-asserted-by":"crossref","unstructured":"Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-\u03b2 antagonist protects mice against metastasis without adverse side effects. J Clin Invest\u20082002; 109: 1607\u201315.","DOI":"10.1172\/JCI200215333"},{"key":"2022061623345656300_B44","doi-asserted-by":"crossref","unstructured":"Bandyopadhyay A, Agyin JK, Wang L, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-\u03b2 type I receptor kinase inhibitor. Cancer Res\u20082006; 66: 6714\u201321.","DOI":"10.1158\/0008-5472.CAN-05-3565"},{"key":"2022061623345656300_B45","doi-asserted-by":"crossref","unstructured":"Nam JS, Suchar AM, Kang MJ, et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor \u03b2 in a mouse model of breast cancer. Cancer Res\u20082006; 66: 6327\u201335.","DOI":"10.1158\/0008-5472.CAN-06-0068"},{"key":"2022061623345656300_B46","doi-asserted-by":"crossref","unstructured":"Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-\u03b2 inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest\u20082002; 109: 1551\u20139.","DOI":"10.1172\/JCI0215234"},{"key":"2022061623345656300_B47","doi-asserted-by":"crossref","unstructured":"Arteaga CL. Inhibition of TGF\u03b2 signaling in cancer therapy. Curr Opin Genet Dev\u20082006; 16: 30\u20137.","DOI":"10.1016\/j.gde.2005.12.009"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/5\/2317\/2867359\/2317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/5\/2317\/2867359\/2317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:59:17Z","timestamp":1655423957000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/5\/2317\/534264\/Stable-Overexpression-of-Smad7-in-Human-Melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2007,3,1]]},"published-print":{"date-parts":[[2007,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-3950","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22371693.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371693","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371690.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22371690","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496890.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496890","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,1]]}}}